All In Biotech

Drug Trial Radar · NCT06311682

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis. The Trial is Randomized, Double-blind, Placebo-controlled, and Parallel-group for Children (Age 2 to <12 Years) and Open-label and Single-group for Infants (Age 6 Months to <2 Years)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

195

Planned (sponsor's estimate)

Start

Jun 10, 2024

Primary completion

Oct 16, 2026

Study completion Apr 28, 2028

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life. The trial will last for up to 4 years. There will be visits every 2 weeks for the first year and every 6 weeks thereafter. Some of the visits will be conducted by phone. The study involves two different age groups: children aged 2 to under 12 years and infants aged 6 months to under 2 years. This trial compares tralokinumab +TCS to placebo + TCS for children with moderate-to-severe AD and evaluates tralokinumab + TCS for infants with moderate-to-severe AD. Infants will not receive placebo. All subjects will go through a screening process, which is the first part of the trial and will last up to 4 weeks. During this period, it will be checked if the child or infant meets the criteria to participate in the trial. The children will be randomly assigned to receive tralokinumab + TCS or placebo + TCS for the initial 16 weeks, with the treatment being double-blinded. During the first 16 weeks, children will have a 2 out of 3 chance of getting tralokinumab and a 1 out of 3 chance of getting placebo. Thereafter, all subjects will receive tralokinumab + TCS. The infants will receive tralokinumab + TCS as open-label treatment for the entire treatment period, meaning that the participants will know they are receiving tralokinumab. After stopping treatment, all participants will enter a 4-week safety follow-up period.

Conditions

  • Atopic Dermatitis

Interventions

  • Tralokinumab + TCSDrug

    The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.

  • Placebo + TCSDrug

    The trial medication will be given under the skin (SC). Dose and dosing frequency for each subject will depend on the subject's body weight. Subjects who will receive treatment every two weeks will receive a loading dose corresponding to a double dose at baseline. Subjects who will receive treatment every 4 weeks will receive a staggered loading dose at baseline and Week 2. After the loading dose, they will continue to receive treatment every 4 weeks. The dose and dosing frequency will be adjusted according to the subject's body weight at weeks 16, 32, 52, 64, 88, 112, 136, 160, and 184.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's Global Assessment for atopic dermatitis (IGA 0/1) score of 0 (clear) or 1 (almost clear) in subjects aged 2 to <12 years at screening.Time frame: At week 16
  2. Having at least 75% reduction in Eczema Area and Severity Index (EASI) score in subjects aged 2 to <12 years at screening.Time frame: At week 16

Locations

72 sites in 13 countries. Site status is shown where the registry gives one.

  • Leo Pharma Investigational site

    Birmingham, Alabama · Recruiting

  • Leo Pharma Investigational site

    North Little Rock, Arkansas · Recruiting

  • Leo Pharma Investigational site

    Palo Alto, California · Recruiting

  • Leo Pharma Investigational site

    Sacramento, California · Recruiting

  • Leo Pharma Investigational site

    San Diego, California · Withdrawn

  • Leo Pharma Investigational site

    San Diego, California · Recruiting

  • Leo Pharma Investigational site

    Jacksonville, Florida · Recruiting

  • Leo Pharma Investigational site

    Miami, Florida · Recruiting

  • Leo Pharma Investigational site

    Tampa, Florida · Recruiting

  • Leo Pharma Investigational site

    Macon, Georgia · Recruiting

  • Leo Pharma Investigational site

    Waterford, Michigan · Recruiting

  • Leo Pharma Investigational site

    Tulsa, Oklahoma · Recruiting

  • Leo Pharma Investigational site

    Portland, Oregon · Recruiting

  • Leo Pharma Investigational site

    Charleston, South Carolina · Recruiting

  • Leo Pharma Investigational site

    Norfolk, Virginia · Recruiting

  • Leo Pharma Investigational site

    Brussels, Belgium · Withdrawn

  • Leo Pharma Investigational site

    Ghent, Belgium · Active not recruiting

  • Leo Pharma Investigational site

    Leuven, Belgium · Withdrawn

  • Leo Pharma Investigational site

    Liège, Belgium · Withdrawn

  • Leo Pharma Investigational site

    Burlington, Canada · Recruiting

  • Leo Pharma Investigational site

    Calgary, Canada · Withdrawn

  • Leo Pharma Investigational site

    Calgary, Canada · Recruiting

  • Leo Pharma Investigational site

    Edmonton, Canada · Recruiting

  • Leo Pharma Investigational site

    Edmonton, Canada · Recruiting

  • Leo Pharma Investigational site

    Hamilton, Canada · Recruiting

  • Leo Pharma Investigational site

    Niagara Falls, Canada · Recruiting

  • Leo Pharma Investigational site

    Saskatoon, Canada · Recruiting

  • Leo Pharma Investigational site

    Windsor, Canada · Recruiting

  • Leo Pharma Investigational site

    Winnipeg, Canada · Recruiting

  • Leo Pharma Investigational site

    Rijeka, Croatia · Active not recruiting

  • Leo Pharma Investigational site

    Zagreb, Croatia · Active not recruiting

  • Leo Pharma Investigational site

    Zagreb, Croatia · Withdrawn

  • Leo Pharma Investigational site

    Buxtehude, Germany · Withdrawn

  • Leo Pharma Investigational site

    Dresden, Germany · Withdrawn

  • Leo Pharma Investigational site

    Mainz, Germany · Withdrawn

  • Leo Pharma Investigational site

    Osnabrück, Germany · Withdrawn

  • Leo Pharma Investigational site

    Tübingen, Germany · Active not recruiting

  • Leo Pharma Investigational site

    Wuppertal, Germany · Withdrawn

  • Leo Pharma Investigational site

    Cork, Ireland · Active not recruiting

  • Leo Pharma Investigational site

    Crumlin, Ireland · Active not recruiting

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.